KALA BIO, Inc.

NasdaqCM:KALA Stock Report

Market Cap: US$22.1m

KALA BIO Management

Management criteria checks 3/4

KALA BIO's CEO is Todd Bazemore, appointed in Nov 2017, has a tenure of 7.5 years. total yearly compensation is $949.55K, comprised of 56.4% salary and 43.6% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth $91.74K. The average tenure of the management team and the board of directors is 7 years and 7.7 years respectively.

Key information

Todd Bazemore

Chief executive officer

US$949.6k

Total compensation

CEO salary percentage56.41%
CEO tenure7.5yrs
CEO ownership0.4%
Management average tenure7yrs
Board average tenure7.7yrs

Recent management updates

Recent updates

Kala Pharmaceuticals to execute reverse stock split

Oct 20

Kala Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

CEO Compensation Analysis

How has Todd Bazemore's remuneration changed compared to KALA BIO's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$950kUS$536k

-US$39m

Sep 30 2024n/an/a

-US$39m

Jun 30 2024n/an/a

-US$39m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$3mUS$536k

-US$42m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$9m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$1mUS$515k

-US$45m

Sep 30 2022n/an/a

-US$80m

Jun 30 2022n/an/a

-US$137m

Mar 31 2022n/an/a

-US$145m

Dec 31 2021US$1mUS$490k

-US$143m

Sep 30 2021n/an/a

-US$126m

Jun 30 2021n/an/a

-US$126m

Mar 31 2021n/an/a

-US$113m

Dec 31 2020US$2mUS$456k

-US$104m

Sep 30 2020n/an/a

-US$95m

Jun 30 2020n/an/a

-US$90m

Mar 31 2020n/an/a

-US$91m

Dec 31 2019US$2mUS$440k

-US$94m

Sep 30 2019n/an/a

-US$98m

Jun 30 2019n/an/a

-US$90m

Mar 31 2019n/an/a

-US$81m

Dec 31 2018US$845kUS$405k

-US$67m

Compensation vs Market: Todd's total compensation ($USD949.55K) is above average for companies of similar size in the US market ($USD681.28K).

Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.

CEO

Todd Bazemore (54 yo)

7.5yrs

Tenure

US$949,550

Compensation

Mr. Todd Bazemore is Interim CEO of KALA BIO, Inc. from February 11, 2025. Mr. Bazemore serves as the Chief Operating Officer of KALA BIO, Inc. (formerly known as Kala Pharmaceuticals, Inc.) since November...

Leadership Team

NamePositionTenureCompensationOwnership
Todd Bazemore
Interim CEO7.5yrsUS$949.55k0.42%
$ 91.7k
R. Brazzell
Head of R&D and Chief Medical Officer12.3yrsUS$920.69k0.44%
$ 98.1k
Justin Hanes
Founder & Chair of the Scientific Advisory Boardno datano datano data
Mary Reumuth
CFO, Treasurer & Secretary11.3yrsno data0.30%
$ 65.2k
Jill Steier
Executive Director of Investor Relations & Corporate Communications3.8yrsno datano data
Vincent Kosewski
Senior VP of Manufacturing & Supply Chain Management7.8yrsno datano data
Darius Kharabi
Chief Business Officer3.5yrsno data0.38%
$ 85.0k
Francis Mah
Chief Medical Advisor2.2yrsno datano data
Josiah Craver
Senior VP & Corporate Controller3.1yrsno datano data
Carl Rennie
Executive Director of Account Management7yrsno datano data
Patrick Bedell
Executive Director of Trade & Alternate Channels7yrsno datano data

7.0yrs

Average Tenure

54yo

Average Age

Experienced Management: KALA's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Justin Hanes
Founder & Chair of the Scientific Advisory Boardno datano datano data
Jonathan Silverstein
Board Observer9.1yrsno datano data
Gregory Perry
Independent Director7.3yrsUS$74.74k0%
$ 0
Peter Hutt
Member of Scientific Advisory Boardno datano datano data
Andrew Koven
Lead Independent Director7.7yrsUS$129.49k0%
$ 0
Ronald Krall
Member of Scientific Advisory Boardno datano datano data
Bennett Shapiro
Member of Scientific Advisory Boardno datano datano data
Colin Gardner
Member of Scientific Advisory Boardno datano datano data
Charles Myers
Independent Director3.6yrsUS$92.24k0%
$ 0
Mark Iwicki
Chairman10.1yrsUS$1.49m1.32%
$ 291.9k
Howard Rosen
Independent Director & Member of Advisory Board11.3yrsUS$99.74k0.0041%
$ 895.9
Marjan Farid
Independent Director2.6yrsUS$84.85k0%
$ 0

7.7yrs

Average Tenure

66yo

Average Age

Experienced Board: KALA's board of directors are considered experienced (7.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/12 00:38
End of Day Share Price 2025/05/12 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

KALA BIO, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Yi ChenH.C. Wainwright & Co.
Raghuram SelvarajuH.C. Wainwright & Co.